“Brincidofovir demonstrated potent virologic activity in patients with adenovirus disease. Subjects treated with brincidofovir appeared to have improved survival vs. historical controls, and there were no new safety signals identified. The data from the pilot portion of this study clearly support progression to the design of the next half of this phase III study for brincidofovir among adenovirus-infected patients,” she concluded.
Dr. Young reported being a clinical investigator and/or receiving research support from Chimerix, GlaxoSmithKline, Merck, and ViroPharma.